osteoporosis Archives -

Market Access/ News/ News

NICE ends UK access disparity to osteoporosis drug Evenity

Phil Taylor Amgen, Evenity, HEOR, NHS, osteoporosis, UCB 0 Comment

NICE has reversed its stance on UCB and Amgen’s severe osteoporosis therapy Evenity, saying out can be prescribed

NICE ends UK access disparity to osteoporosis drug Evenity

https://pharmaphorum.com/news/nice-ends-uk-access-disparity-to-osteoporosis-drug-evenity/

Digital/ News/ News

UCB licenses AI tech for spinal fracture detection to ImageBiopsy

Phil Taylor bone, diagnostic, digital, digital health, ImageBiopsy Lab, osteoporosis, UCB 0 Comment

An artificial intelligence-based tool for identifying hard-to-detect spinal fractures, developed by Belgian drugmaker UCB, has been licensed out

UCB licenses AI tech for spinal fracture detection to ImageBiopsy

https://pharmaphorum.com/news/ucb-licenses-ai-tech-for-spinal-fracture-detection-to-imagebiopsy/

News

UCB/Amgen’s Evenity approved in Europe after appeal

Richard Staines Amgen, osteoporosis, UCB 0 Comment

UCB and Amgen’s osteoporosis drug Evenity has finally been approved in Europe, following a successful appeal against a

UCB/Amgen’s Evenity approved in Europe after appeal

https://pharmaphorum.com/news/ucb-amgens-evenity-approved-in-europe-after-appeal/

News/ Top stories

Patient voice overcomes EU ‘no’ for UCB/Amgen’s osteoporosis drug

Richard Staines Amgen, osteoporosis, regulation, UCB 0 Comment

UCB/Amgen’s osteoporosis drug Evenity (romosozumab) looks set for approval in Europe after regulators finally recommended it, following a

Patient voice overcomes EU ‘no’ for UCB/Amgen’s osteoporosis drug

https://pharmaphorum.com/news/ucb-overcomes-eu-no-for-osteoporosis-drug-with-patient-testimony/

Partner content/ Patients/ Press releases

Vitamin K Market will reach over $1,000 million by 2025

Jignesh Thakkar osteoporosis, Vitamin K Market, Vitamin K1, Vitamin K2, Vitamin-K Dependent Clotting Factor Deficiency 0 Comment

Vitamin K Market will achieve over 8% CAGR up to 2025

Vitamin K Market will reach over $1,000 million by 2025

https://pharmaphorum.com/partner-content/vitamin-k-market-will-reach-over-1000-million-by-2025/

Market Access/ News/ News

Lilly faces biosimilar rivals to osteoporosis drug Forsteo in Europe

Phil Taylor biosimilar, Eli Lilly, Gedeon Richter, osteoporosis 0 Comment

Two biosimilars of Eli Lilly’s blockbuster osteoporosis treatment Forsteo – from Hungary’s Gedeon Richter and German partner Stada

Lilly faces biosimilar rivals to osteoporosis drug Forsteo in Europe

https://pharmaphorum.com/news/lilly-faces-biosimilar-rivals-to-osteoporosis-drug-forsteo-in-europe/

News/ News

CHMP says no to Amgen’s osteoporosis drug Evenity

Phil Taylor Amgen, Evenity, osteoporosis, UCB 0 Comment

Amgen and UCB have suffered another setback as they try to build momentum for Evenity, their new antibody

CHMP says no to Amgen’s osteoporosis drug Evenity

https://pharmaphorum.com/news/chmp-says-no-to-amgens-osteoporosis-drug-evenity/

Market Access/ News/ News/ Top stories

At long last, Amgen/UCB score FDA okay for Evenity

Phil Taylor Amgen, Evenity, osteoporosis, UCB 0 Comment

Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down

At long last, Amgen/UCB score FDA okay for Evenity

https://pharmaphorum.com/news/at-long-last-amgen-ucb-score-fda-okay-for-evenity/

News

FDA advisers back Amgen/UCB’s osteoporosis drug Evenity

Richard Staines Amgen, osteoporosis 0 Comment

Amgen’s bone-building drug Evenity looks on course for US approval in certain women with osteoporosis after a panel

FDA advisers back Amgen/UCB’s osteoporosis drug Evenity

https://pharmaphorum.com/news/fda-advisers-back-amgen-ucbs-osteoporosis-drug-evenity/

Trending

osteoporosis

Login